A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to determine the effect of BMS-582664 on patients
with hepatocellular carcinoma with varying levels of hepatic impairment